癌症治療

Central to the company’s approach is its groundbreaking “International Four-Dimensional (4D) Therapy” platform, redefining traditional cancer treatment paradigms. This advanced framework comprises four therapeutic dimensions designed to attack cancer comprehensively:

With these globally safeguarded therapeutic advances and a distinguished multidisciplinary team, the company is uniquely positioned as a leader in next-generation cancer therapeutics, committed to delivering sophisticated, effective and personalised patient care.

Cancer’s curability depends on its type, stage and treatment. Some cancers, such as early-stage breast or prostate cancer, can often be cured with surgery, radiation or chemotherapy, achieving long-term remission. However, a universal cure for all cancers does not exist, and recurrence remains a risk.

Advanced stages or aggressive cancers, such as pancreatic cancer, are less likely to be cured. Ongoing research continues to improve outcomes, but cancer is complex, with more than 200 types.

Source: American Cancer Society (2021). This information is for general education and does not replace advice from a qualified clinician.

Each dimension of 4D Therapy targets a different vulnerability in cancer biology. The sections below summarise the rationale, clinical applications and potential advantages of each mechanism.

Cancer cells rewire metabolism to support rapid growth, often relying on aerobic glycolysis—the Warburg effect—as well as glutaminolysis and increased fatty-acid synthesis. Oncogenes such as MYC and RAS, and the loss of tumour suppressors, help tumours thrive in nutrient-poor, hypoxic conditions, creating distinct metabolic vulnerabilities.

Therapies targeting glycolysis, glutamine dependence and amino-acid dependence are in development or in clinical use. Examples include IDH1/2 inhibitors in IDH-mutant leukaemias and gliomas, and L-asparaginase in leukaemia. Metabolic strategies are also being studied alongside chemotherapy, targeted therapy and immunotherapy.

Smart nano-targeting uses nanoparticle-based carriers, typically 10–100 nm in size, to deliver therapeutic agents to cancer cells while sparing normal tissue. Active targeting attaches antibodies, peptides or aptamers that bind receptors overexpressed on tumour cells; passive targeting exploits leaky tumour vasculature.

Nanotechnology-based cancer therapies are already in clinical use. Liposomal chemotherapy, albumin-bound paclitaxel and antibody-drug conjugates all use targeted delivery to improve the therapeutic index. Newer carriers are being designed to release their payload in response to the tumour microenvironment.

Targeted delivery can concentrate treatment at the tumour site, potentially improving efficacy while reducing systemic toxicity. It may also help overcome biological barriers that limit the penetration of conventional drugs.

The tumour microenvironment includes blood vessels, immune cells, fibroblasts and the extracellular matrix. Tumours use this environment to suppress immunity and support growth. Remodelling strategies aim to normalise vasculature, reduce immunosuppressive factors and improve the penetration of drugs and immune cells.

Anti-angiogenic therapy, TGF-β inhibition, macrophage depletion and adenosine-pathway blockade are among the approaches being studied. Low-dose metronomic chemotherapy and radiotherapy can also act as microenvironment modulators, turning immunologically “cold” tumours into more responsive ones.

Because non-cancerous cells in the microenvironment are genetically more stable than cancer cells, they are less likely to acquire resistance. Targeting this supportive network can therefore complement chemotherapy, radiotherapy and immunotherapy.

Comprehensive care. Support spans early screening, treatment and long-term management, including rehabilitation and psychological care.

Clinical trials. Patients may be considered for international multicentre research and advanced oncology care at partner hospitals.

AllCancer 主要處理具有代謝異常的實體腫瘤，包括乳癌、肺癌、大腸癌、前列腺癌及肝癌等常見癌症；腦、肝、骨轉移等轉移性及難治性腫瘤；抗藥性腫瘤；以及胰臟癌、卵巢癌、胃癌等其他實體腫瘤。是否適合治療，需按個別病情評估。

Submit the secure appointment form with the patient’s diagnosis, stage, imaging and previous treatment records. A case manager will review the information and contact you to arrange a consultation.

Please bring recent imaging reports, pathology results, blood tests, a current medication list and a summary of previous treatments. These records help the clinical team assess whether the 4D programme is appropriate.

Our case managers will review the diagnosis, stage and previous treatment records before arranging a consultation.